Incanthera Ltd
Records under this name other than patents Incanthera Ltd holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,956,296 | Compounds containing a vascular disrupting agent Formerly held Lapsed on the fee record Ended May 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2026 | From the USPTO record |
| US 9,937,267 | Methods of treating cancer using compounds containing a vascular disrupting agent Formerly held Lapsed on the fee record Ended Apr 10, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 10, 2026 | From the USPTO record |
| US 8,691,751 | Compounds containing a vascular disrupting agent Formerly held Lapsed on the fee record Ended Apr 8, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 8, 2026 | From the USPTO record |
| US 10,912,839 | Methods of treating cancer using compounds containing a vascular disrupting agent Formerly held Lapsed on the fee record Ended Feb 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 9, 2025 | From the USPTO record |
| US 9,358,303 | Compounds containing a vascular disrupting agent Formerly held Lapsed on the fee record Ended Jun 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 7, 2024 | From the USPTO record |
| US 10,556,014 | Compounds containing a vascular disrupting agent Formerly held Lapsed on the fee record Ended Feb 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 11, 2024 | From the USPTO record |
| US 7,192,977 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment Term ended Term ended May 8, 2023 · From the USPTO record | Term ended | Term ended May 8, 2023 | From the USPTO record |
| US 10,201,622 | Tumour-targeted theranostic Formerly held Lapsed on the fee record Ended Feb 12, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2023 | From the USPTO record |
| US 8,927,486 | Compounds Formerly held Lapsed on the fee record Ended Jan 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jan 6, 2023 | From the USPTO record |
| US 7,626,026 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment Lapsed on the fee record Ended Dec 1, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 1, 2021 | From the USPTO record |